Enanta Pharmaceuticals Inc (ENTA): ENTA’s pro forma cash @3/31/23=$454M

Next 10 Prev Next

Send PM Follow Ignore

Followers	843
Posts	122815
Boards Moderated	10
Alias Born	09/05/2002

DewDiligence

Re: None

Tuesday, 05/16/2023 6:19:33 PM

Tuesday, May 16, 2023 6:19:33 PM

ENTA’s pro forma cash @3/31/23=$454M—an increase of $166.4M* since 12/31/22. The $454M figure consists of:

• $239.0M of net current assets on the 3/31/22 balance sheet (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001177648/000095017023019842/enta-20230331.htm#consolidated_balance_sheets );

• $15.0M of marketable securities on the 3/31/23 balance sheet designated as long-term (e.g. bonds with a time to maturity greater than one year) (ibid); and

• $200M proceeds from partial monetization of the Mavyret royalty stream (#msg-171766236), which was announced on 4/25/23 and hence was not reflected in the 3/31/23 balance sheet.

*Excluding the $200M proceeds from the Mavyret royalty monetization, ENTA pro forma cash at 3/31/23 declined by $33.6M relative to $12/31/22.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”